Lawrence David Sher MD

Allergy & Immunology•Rolling Hills Estates, CA

Asthma & Allergic Conditions, Pediatric Asthma & Allergic Conditions

Palos Vedes Medical Group

Join to View Full Profile

501 Deep Valley DrSuite 210Rolling Hills Estates, CA 90274
Phone+1 310-544-6858
Fax+1 310-544-6855

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Allergy and Immunology, 1986 - 1989
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1983 - 1986
University of Utah School of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1984 - 2025
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Start of enrollment: 2004 Oct 01
Completed
Phase 3
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Start of enrollment: 2004 Oct 01
Completed
Phase 3
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine Start of enrollment: 2007 Sep 01
Completed
Phase 3
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl Start of enrollment: 2011 Sep 19
Completed
Phase 3
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder Start of enrollment: 2012 Apr 03
Completed
Phase 4
A Study of ARRY-502 in Patients With Persistent Asthma Start of enrollment: 2012 Apr 02
Completed
Phase 2
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma Start of enrollment: 2012 Jul 01
Completed
Phase 2
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma Start of enrollment: 2014 Nov 01
Terminated
Phase 2
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Start of enrollment: 2017 Nov 02
COMPLETED
PHASE3
AR101 Real-World Open-Label Extension Study Start of enrollment: 2017 Oct 18
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Start of enrollment: 2018 Jan 21
TERMINATED
PHASE3
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy Start of enrollment: 2019 Aug 20
Terminated
Phase 2
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma Start of enrollment: 2020 Jul 16
Completed
Phase 4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).
Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, Dareen Siri, Roxanne C Oriel
The Journal of Allergy and Clinical Immunology. in Practice. 2025-02-27
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.
Mark Boguniewicz, Lawrence D Sher, Amy S Paller, Peter D Arkwright, Shigemi Yoshihara
Advances in Therapy. 2024-12-01
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.
Lawrence D Sher, Justice K Boakye-Appiah, Sungeen Hill, Emily Wasserman, Xia Xu
Journal of the Pediatric Infectious Diseases Society. 2024-08-24

Press Mentions

OCS-Sparing Effect of Dupilumab for Severe Asthma MaintainedJuly 23rd, 2022
Pandemic-Weary LA County Crestfallen over News of Masks’ Return, Mere Weeks After Restrictions EasedJuly 15th, 2021
Are We Declaring Pandemic over Too Fast? California’s June 15 Deadline for Reopening Splits ExpertsApril 8th, 2021
Join now to see all